Biotech

All Articles

Zephyrm seeks Hong Kong IPO to cash phase 3 tissue treatment tests

.Zephyrm Bioscience is gusting towards the Hong Kong stock exchange, submission (PDF) for an IPO to ...

Frazier Life Sciences gets $630M for small, mid-cap biotechs

.Frazier Daily life Sciences has sourced an even further $630 thousand for its fund paid attention t...

GigaGen achieves approximately $135M BARDA money to beat botox

.Antibody fan GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its own technology to ...

GPCR organization Septerna apply for IPO on toughness of preclinical information

.Septerna will learn just how a biotech without "any sort of purposeful medical data" fares in the l...

Kurma closes to begin with $154M payload for largest biotech fund as yet

.International VC agency Kurma Allies has unveiled its newest biotech fund, with 140 thousand euros ...

Prothena promotes one director while one more places-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of significant management hirings, shootings ...

Editas cashes in on Vertex Cas9 licensing civil liberties for $57M

.Against the background of a Cas9 license fight that declines to die, Editas Medication is cashing i...

Ultragenyx tweaks gene treatment application to dial up efficacy

.A minority of patients taking Ultragenyx Pharmaceutical's Wilson illness gene treatment UX701 have ...

Biopharma cutback fee maintains in Q3: Fierce Biotech study

.As summer season heat energy turns to cool winds, hopes that this year would take common sector com...

J &amp J falls phase 2 dengue applicant in latest shift coming from injections

.Johnson &amp Johnson's deprioritization of its own transmittable health condition pipeline has actu...